Physician profile
Ryan Allen Baker
NPI 1457778383
$3,721.28
in general payments reported to CMS, 2019-2025
19 companies · $612 in 2025
The $612 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.08 · 2021: $54.83 · 2022: $257 · 2023: $2,217 · 2024: $561 · 2025: $612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,656 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,400 · Consulting Fee: $300 · Travel and Lodging: $33.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,656.32 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,400.00 |
| Consulting Fee | $300.00 |
| Travel and Lodging | $33.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $2,582.56 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $436.63 | 2022-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $103.53 | 2023-2024 | Jornay Pm |
| Neos Therapeutics, LP | $92.89 | 2022-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Tris Pharma INC | $61.33 | 2022-2025 | Dyanavel Xr, Onyda Xr |
| Sumitomo Pharma America, INC. | $55.06 | 2023 | Orgovyx |
| Alk-Abello, INC | $48.07 | 2025 | Neffy, Odactra, Grastek |
| Kaleo, INC. | $46.59 | 2021-2023 | Auvi-Q |
| Verrica Pharmaceuticals INC. | $46.01 | 2024-2025 | Ycanth |
| Collegium Pharmaceutical, INC. | $36.55 | 2025 | Jornay Pm |
| Astrazeneca Pharmaceuticals LP | $34.81 | 2024 | Flumist Quadrivalent |
| Phadia US INC. | $34.19 | 2023-2025 | Immunocap |
| Abbvie INC. | $26.14 | 2022 | |
| Hologic Sales and Service, LLC | $25.81 | 2024 | Aptima, Thinprep 2000 Processor |
| Sobi, INC | $22.10 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saol Therapeutics INC. | $19.08 | 2019 | |
| Pfizer INC. | $18.25 | 2022 | |
| Vertical Pharmaceuticals, LLC | $17.24 | 2024 | Relexxii |
| Merck Sharp & Dohme LLC | $14.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.